Kelyniam Global Outperforms Q1 Expectations, Strikes Licensing Deal with Bioplate for Innovative Osteopore Products

Kelyniam Global (OTC: KLYG), a pioneer in custom cranial implants, has released its financial report for the quarter ending March 31, 2023. The company continues to lead the industry with its innovative approach to cranial implants, empowering patients around the world with custom-built solutions.

Kelyniam is thrilled to announce the expansion of its licensing agreement with Bioplate, which will enable the company to sell revolutionary Osteopore products in select U.S. markets, including New York, New Jersey, Massachusetts, Maryland and Florida.

CEO Ross Bjella sees the adoption of these unique osteo-integrative solutions such as Osteostrip, Osteoplug, and Osteomesh as a major step in diversifying the Kelyniam product lineup and addressing unmet clinical needs within the cranio-facial field.

Bioplate and Kelyniam have just expanded their current agreement to provide a cutting-edge solution to surgeons in the United States – Osteopore Ltd’s revolutionary implants. These implants, made with patented technology that dissolves over time, leave only natural, healthy bone tissue and drastically reduce the risk of complications associated with permanent bone implants. Now, surgeons in the US can have access to this groundbreaking procedure.

Kelyniam experienced a dip in revenue in the quarter, with January sales falling below expectations. However, February and March saw a notable rebound, yet the earlier dip was still not enough to match the prior year’s growth.

Market conditions, such as weather, surgeon availability and patient scheduling, often mean that monthly sales can fluctuate through the year. Despite the near-term fluctuations, the company is bullish on PEAK implant revenue – expecting typical growth throughout 2023.

For the year ended March 31, 2023, take a look at the financial highlights compared to the same period in 2022! Discover the changes in finances and gauge how your investments have done over the course of the year.

We have seen a drop of 9.2% in revenue, with our total revenue for the period plummeting from $656,858 to $596,455.

Our gross margin has decreased from $509,201 to $467,773, representing a decrease of nearly 8%. Despite this decline, we remain focused on driving growth and maximizing our profitability.

The company saw a 10-fold increase in losses as they reported an operating loss of $67,978, in comparison to the loss of $5,924 reported in the previous year.

Desiree Webb has been promoted to Chief Operating and Revenue Officer at the company, taking on the responsibility of both sales and operations. Prior to her new post, Webb was the Vice President of Sales and is now equipped to lead the company to more success.

Kelyniam Inc. is revolutionizing the healthcare industry with their creative use of computer aided design and computer aided manufacturing to rapidly create custom medical-grade prosthetics and implants for patients.

Working closely with leading surgeons, healthcare systems and payors, the company is striving to improve patient outcomes and reduce the cost of care. With their advanced cranial and maxillo-facial products taking center stage, Kelyniam is leading the way to a safer and healthier future.

Leave a Comment